Approval

Notice - RAYMOND POMROY, File No. 2024-3

Retrieved on: 
Friday, March 8, 2024

TORONTO, March 8, 2024 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above- named matter approving the Settlement Agreement reached between Staff of the Commission and Raymond Pomroy.

Key Points: 
  • TORONTO, March 8, 2024 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above- named matter approving the Settlement Agreement reached between Staff of the Commission and Raymond Pomroy.
  • A copy of the Order dated March 8, 2024, Settlement Agreement dated February 26, 2024 and Oral Reasons for Approval of a Settlement dated March 8, 2024 are available at capitalmarketstribunal.ca

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
Wednesday, January 31, 2024

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

Notice - NICHOLAS AGAR and PAUL UNGERMAN, File No. 2024-1

Retrieved on: 
Monday, January 29, 2024

TORONTO, Jan. 29, 2024 /CNW/ - The Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission, Nicholas Agar and Paul Ungerman in the above-named matter.

Key Points: 
  • TORONTO, Jan. 29, 2024 /CNW/ - The Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission, Nicholas Agar and Paul Ungerman in the above-named matter.
  • A copy of the Order dated January 26, 2024, Settlement Agreement dated January 10, 2024 and Reasons for Approval of a Settlement dated January 26, 2024 are available at capitalmarketstribunal.ca

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
Monday, January 22, 2024

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.

Red White & Bloom Brands Transitions to International Cannabis Company Through Closing of Aleafia Transaction

Retrieved on: 
Monday, January 15, 2024

TORONTO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB”) is pleased to announce that, in connection with the proceedings of Aleafia Health Inc. (“Aleafia Health”) and certain of its subsidiaries (collectively, the “Aleafia Group”) under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”), the parties have successfully closed the previously announced sale transaction (the “Transaction”), as further described below.

Key Points: 
  • “The accretive nature of the Transaction has been evident to RWB management since the inception of the relationship with the Aleafia group of companies.
  • With the closing behind us, the combined, dedicated RWB and Aleafia teams are focused on delivering accessible synergies focused within sales, production, procurement, and marketing."
  • One of Canada’s largest virtual medical cannabis clinics that provides quality cannabis products to patient subscribers in a convenient and low-cost setting.
  • An established portfolio of loyal cannabis brands in both adult use (recreational) and medical channels.

Hut 8 receives court approval in its stalking horse bid for four natural gas power plants including the North Bay Bitcoin mine

Retrieved on: 
Monday, January 8, 2024

Among other things, the Approval and Vesting Order approves the Company's previously announced stalking horse bid transaction (the "Transaction") to acquire four natural gas power plants including the North Bay Bitcoin mine, which was submitted in partnership with Macquarie Equipment Finance Ltd. (“Macquarie”), a subsidiary of Macquarie Group Limited, a global financial services group.

Key Points: 
  • Among other things, the Approval and Vesting Order approves the Company's previously announced stalking horse bid transaction (the "Transaction") to acquire four natural gas power plants including the North Bay Bitcoin mine, which was submitted in partnership with Macquarie Equipment Finance Ltd. (“Macquarie”), a subsidiary of Macquarie Group Limited, a global financial services group.
  • In connection with the approval of the Transaction, a new Ontario subsidiary of Hut 8 ("BidCo") will become the owner of certain assets of VPC and the assets and operations and equity interests of certain Validus Entities.
  • Completion of the Transaction remains subject to the satisfaction of other standard conditions to closing.
  • The completion of the Transaction, which is anticipated to occur by February 15, 2024, is also expected to result in the full and final resolution of all litigation claims and counterclaims currently pending between Hut 8 and certain Validus Entities.

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting

Retrieved on: 
Saturday, December 30, 2023

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting

Key Points: 
  • Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
    Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
    Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM).
  • The shareholders approved with large majorities (see details below) all proposals put forward by the Board of Directors: In particular, the sale by Evolva Holding SA of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., was approved which secures the future of Evolva’s operations.
  • We would like to thank the Evolva shareholders for their support in securing the future of Evolva AG’s operations.”
    The convocation of an EGM became necessary after Evolva Holding SA signed, on 20 November 2023, a share purchase agreement with Danstar Ferment AG regarding the sale of all shares in Evolva Holding SA’s wholly owned subsidiary Evolva AG.
  • Agenda item 5 (Delisting of Evolva Holding SA from SIX Swiss Exchange): with 91.10% of the votes represented (votes represented: 3,052,011 votes of the total outstanding shares/votes of 6,827,012).

Red White & Bloom Provides Update Relating to Aleafia Health and Other Corporate Matters

Retrieved on: 
Tuesday, October 31, 2023

TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) is providing an update on matters relating to Aleafia Health Inc. (“Aleafia Health”) and other corporate matters.

Key Points: 
  • TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) is providing an update on matters relating to Aleafia Health Inc. (“Aleafia Health”) and other corporate matters.
  • The Approval and Vesting Order approves the implementation of the transactions contemplated by the Amended Stalking Horse Agreement, whereby a wholly-owned subsidiary of RWB would subscribe for shares of the Aleafia Purchased Entities and acquire specific intellectual property owned, licensed or leased by Aleafia Health.
  • Certain excluded assets and liabilities of the Aleafia Purchased Entities would be transferred to one or more corporations that would not be included among the Aleafia Purchased Entities at closing.
  • RWB’s subsidiary would be the sole shareholder of the Aleafia Purchased Entities following closing.

Notice - ROYAL BANK OF CANADA, File No. 2023-32

Retrieved on: 
Friday, November 3, 2023

TORONTO, Nov. 3, 2023 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission and Royal Bank of Canada.

Key Points: 
  • TORONTO, Nov. 3, 2023 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission and Royal Bank of Canada.
  • A copy of the Order dated November 3, 2023, Settlement Agreement dated October 25, 2023 and Oral Reasons for Approval of a Settlement dated November 3, 2023 are available at capitalmarketstribunal.ca

Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency

Retrieved on: 
Monday, August 21, 2023

The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union as well as Iceland, Norway and Liechtenstein.

Key Points: 
  • The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union as well as Iceland, Norway and Liechtenstein.
  • The Orphan Disease Designation (ODD) was approved to treat Esophageal Atresia, a congenital disorder where children are born with an incomplete, underdeveloped esophagus.
  • Sponsor's may also have access via orphan designation to conditional approval, which is conducted under the centralized procedure.
  • Authorized orphan medicines benefit from ten years of protection from market competition with similar medicines with similar indications once they are approved.